Valuation : Novartis AG

Market Cap 307B 265B 249B 227B 426B 29,115B 429B 2,943B 1,145B 14,810B 1,152B 1,127B 49,107B P/E 2026 *
22.9x
P/E 2027 * 19.5x
Enterprise Value 339B 293B 275B 251B 472B 32,216B 474B 3,256B 1,267B 16,388B 1,274B 1,247B 54,339B EV / Sales 2026 *
5.89x
EV / Sales 2027 * 5.46x
Free-Float
91.66%
Yield 2026 *
2.71%
Yield 2027 * 2.82%
1 day+6.19%
1 week+2.00%
Current month+6.19%
1 month+3.25%
3 months+14.34%
6 months+0.21%
Current year+19.15%
1 week 122.88
Extreme 122.88
132.24
1 month 121.38
Extreme 121.38
132.24
Current year 107.88
Extreme 107.88
132.24
1 year 96.15
Extreme 96.15
132.24
3 years 81.55
Extreme 81.55
132.24
5 years 73.14
Extreme 73.14
132.24
10 years 68.07
Extreme 68.07
132.24
Manager TitleAgeSince
Chief Executive Officer 50 2018-01-31
Director of Finance/CFO - 2026-03-15
Compliance Officer 58 2025-04-13
Director TitleAgeSince
Director/Board Member 67 2014-12-31
Director/Board Member 69 2015-12-31
Director/Board Member 61 2015-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+6.19%+2.00% - - 290B
+0.28%-5.97%+58.34%+108.22% 1,031B
+2.01%-0.71%+53.07%+68.99% 641B
+1.39%-2.18%+23.57%+75.43% 453B
-1.50%-7.04%+33.55%+33.94% 349B
+6.25%+2.04%+28.97%+46.57% 290B
-0.07%-4.12%+0.95%+11.79% 252B
+1.92%-0.93%+52.28%+70.67% 232B
+0.51%-4.52%-19.50%-54.83% 201B
+2.45%+0.77%+32.71%+95.59% 181B
Average +2.07%-2.91%+29.33%+50.71% 403.31B
Weighted average by Cap. +1.94%-3.40%+38.39%+66.40%

Financials

2026 *2027 *
Net sales 57.65B 49.73B 46.78B 42.61B 80.14B 5,471B 80.57B 553B 215B 2,783B 216B 212B 9,228B 61.31B 52.88B 49.75B 45.32B 85.22B 5,819B 85.68B 588B 229B 2,960B 230B 225B 9,814B
Net income 13.95B 12.03B 11.32B 10.31B 19.39B 1,324B 19.5B 134B 52.09B 674B 52.38B 51.24B 2,233B 15.5B 13.37B 12.58B 11.46B 21.55B 1,471B 21.67B 149B 57.88B 748B 58.2B 56.94B 2,482B
Net Debt 32.68B 28.19B 26.52B 24.16B 45.43B 3,102B 45.67B 313B 122B 1,578B 123B 120B 5,231B 27.82B 24B 22.57B 20.56B 38.67B 2,640B 38.88B 267B 104B 1,343B 104B 102B 4,453B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
75,267
Date Price Change Volume
26-09-01 CHF 130.78 +6.19% 130,000
26-08-31 CHF 123.16 -0.71% 130,000
26-08-28 CHF 124.04 -0.85% 130,000
26-08-27 CHF 125.10 -2.43% 130,000
26-08-26 CHF 128.22 0.00% 130,000
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
161.40USD
Average target price
154.40USD
Spread / Average Target
-4.33%

Quarterly revenue - Rate of surprise